Ipsen

Ipsen (Euronext: IPN) is a global specialty-care biopharmaceutical company focused on bringing transformative medicines to patients in three therapeutic areas: Oncology, Rare Disease and Neuroscience. The company was founded nearly 100 years ago and is headquartered in Paris, France. Ipsen has a direct commercial presence in more than 30 countries and its medicines are available in over 100 countries worldwide. The company is listed on Euronext Paris and has a Sponsored Level I American Depositary Receipt program trading in the US under the symbol IPSEY.

Ipsen's key products and services include:

• Cabometyx (cabozantinib): A tyrosine kinase inhibitor used to treat various cancers including renal cell carcinoma and hepatocellular carcinoma

• Onivyde (irinotecan): Used to treat metastatic pancreatic cancer

• Somatuline (lanreotide): Used to treat neuroendocrine tumors and acromegaly

• Dysport (abobotulinumtoxinA): A botulinum toxin used for various therapeutic and aesthetic indications

• Decapeptyl (triptorelin): Used to treat prostate cancer, endometriosis, uterine fibroids and other conditions

• Bylvay (odevixibat): Used to treat progressive familial intrahepatic cholestasis

In the first half of 2024, Ipsen reported total sales growth of 9.5% at constant exchange rates, driven by strong performances of Cabometyx and Dysport. The company upgraded its full-year 2024 guidance, now expecting total sales growth greater than 7% at constant currency. Ipsen continues to expand its pipeline through external innovation, including the recent in-licensing of tovorafenib for pediatric low-grade glioma. The company is focused on launching new products like Onivyde in first-line pancreatic cancer and Iqirvo in primary biliary cholangitis in 2024.